AN umbrella organisation whose members comprise of major pharmaceutical companies in Cyprus has revised its Code of Practice to include stricter provisions on the promotion of prescription medicines.
KEFEA’s new code, available on the association’s website, www.kefea.org.cy, lays the foundation for stricter self-regulation within the framework of European efforts to increase transparency and credibility in the pharmaceutical industry, a news release said.
Compliance is obligatory for KEFEA members as well as members of the European federation of pharmaceutical industries and associations (EFPIA), of which KEFEA is a member.
Joanna Kozakou, head of KEFEA, said the new code includes stricter provisions on the interaction between medical representatives and healthcare professionals, the promotion of prescriptions of medicinal products, the availability of samples as well as promotional material and hosting of healthcare professionals during scientific events.
KEFEA was established in 2006 and its members are GSK, Lilly, Novartis, Pfizer, Sanofi and Amgen Hellas.
Health minister Petros Petrides recently said they were looking for Cyprus to place medication and supplies orders along with Greece to take advantage of lower prices. Petrides said he has been in touch with authorities in Greece to discuss joint purchases of medicines, which in Cyprus may be three times more expensive than in Greece.